Semaglutide and Sleep Apnea: How GLP-1 Treatment Affects Sleep
Obstructive sleep apnea and obesity are closely connected — around 70% of people with OSA have obesity, and excess tissue around the neck and upper airway is one of the primary drivers of the condition. GLP-1 medications are now producing some of the most substantial data on sleep apnea improvement outside of bariatric surgery. Here is what the evidence actually shows, and what it does not.
Key takeaways
Obesity and obstructive sleep apnea (OSA) overlap heavily — roughly 40% of people with obesity have OSA, and about 70% of people with OSA have obesity.
The SURMOUNT-OSA trials (Malhotra et al., NEJM, 2024) studied tirzepatide — not semaglutide — and reported a mean AHI reduction of up to 62.8% versus placebo over 52 weeks.
Weight loss is understood to be the primary mechanism — reductions in AHI tracked with the amount of weight lost.
Do not stop using CPAP because you started a GLP-1 medication. Any change to OSA treatment requires reassessment by the physician managing your sleep apnea.
The connection between obesity and sleep apnea
Obstructive sleep apnea is caused by the collapse of the upper airway during sleep, temporarily interrupting breathing and fragmenting sleep. Excess tissue around the neck, tongue, and upper airway is a primary anatomical driver — and unlike many risk factors, it is modifiable.
Longstanding research in this area, including work by Peppard and colleagues, established that weight change and OSA severity move together: weight gain is associated with worsening of the apnea–hypopnea index (AHI, the standard clinical measure of OSA severity), and weight loss with improvement. This relationship is the basis for weight management being part of OSA care alongside airway therapy.
OSA is also a qualifying comorbidity under FDA labeling for the brand-name weight-management medications Wegovy and Zepbound at a BMI of 27 or higher — meaning patients with OSA and overweight or obesity fall within the labeled indication for those products.
What the SURMOUNT-OSA trials found
The most rigorous evidence to date on GLP-1 medications and sleep apnea comes from SURMOUNT-OSA, published in the New England Journal of Medicine (Malhotra et al., 2024). Two 52-week, randomized, double-blind, placebo-controlled trials evaluated tirzepatide at a maximum tolerated dose of 10mg or 15mg in adults with moderate-to-severe OSA and obesity.
Important scope note
SURMOUNT-OSA studied tirzepatide, not semaglutide, and it studied the FDA-approved product — not compounded versions. Its findings cannot be transferred directly to semaglutide or to compounded medications, neither of which has been evaluated in an equivalent OSA trial.
SURMOUNT-OSA key findings (Malhotra et al., NEJM, 2024)
Study 1 enrolled participants not using positive airway pressure (PAP) therapy. Study 2 enrolled participants who were using PAP and planned to continue during the trial.
Across both studies, tirzepatide met all primary and key secondary endpoints, with a mean AHI reduction of up to 62.8% versus placebo — roughly 30 fewer breathing events per hour of sleep.
In a key secondary endpoint, 43.0% of participants in Study 1 and 51.5% in Study 2 receiving tirzepatide met the trial's criteria for disease resolution.
Participants also showed improvements in hypoxic burden, sleep-related patient-reported outcomes, high-sensitivity C-reactive protein, and systolic blood pressure.
The trial investigators and subsequent commentary have noted that it remains an open question how much of the AHI improvement is attributable to weight loss alone versus other effects — the relationship between the degree of AHI improvement and the magnitude of weight reduction is still being explored.
What about semaglutide specifically?
This is where the evidence thins considerably, and it is worth being direct about that.
SURMOUNT-OSA studied tirzepatide. There is no equivalent phase 3 trial of semaglutide with polysomnography-measured OSA endpoints. The mechanism most likely at work — reduced upper airway fat and improved respiratory mechanics following significant weight loss — is not drug-specific in principle, and semaglutide produces substantial weight loss in trials of the brand-name product. But "the mechanism should apply" is a reasonable expectation, not a demonstrated result.
What can be said fairly: weight loss of the magnitude semaglutide produces is associated with OSA improvement in the broader literature. What cannot be said: that semaglutide has been shown in a dedicated trial to reduce AHI or produce OSA remission at any particular rate. If you have OSA and are considering GLP-1 treatment, that distinction is worth raising with your provider.
Does GLP-1 treatment mean I can stop using CPAP?
No — not on your own, and not based on starting a medication or seeing early weight loss.
CPAP should not be discontinued because you began GLP-1 treatment. Any decision to reduce pressure settings or stop PAP therapy requires repeat testing (polysomnography or a home sleep apnea test) under the supervision of the physician managing your sleep apnea. Untreated OSA carries real cardiovascular and daytime-safety risk, including increased risk of motor vehicle and work-related injury.
The right sequence
Continue your prescribed OSA treatment. Work with your provider on your weight management plan. After a period of sustained weight loss, ask your sleep medicine physician whether repeat testing is appropriate to reassess your OSA severity. Let that result — not the scale, and not this article — drive any change to your CPAP.
Sleep apnea, sleep quality, and weight loss outcomes
The relationship runs in both directions. Untreated or undertreated OSA fragments sleep, and poor sleep is associated with increased appetite-related hormone signaling, reduced insulin sensitivity, and greater difficulty sustaining the behaviors that support weight loss. Patients with undertreated OSA may find weight loss harder than those whose sleep is being treated.
If you have been diagnosed with sleep apnea and are not using your CPAP consistently, that is worth addressing alongside GLP-1 treatment — not instead of it. The two are complementary.
Frequently asked questions
Can semaglutide cure sleep apnea?
No medication should be described as curing OSA, and semaglutide has not been studied in a dedicated OSA trial. What the evidence supports is that significant weight loss is associated with reduced OSA severity. In SURMOUNT-OSA — which studied tirzepatide, not semaglutide — 43.0% of participants in Study 1 and 51.5% in Study 2 met the trial's criteria for disease resolution at 52 weeks. Whether your own OSA improves, and by how much, is something only repeat sleep testing can establish.
Does semaglutide help you sleep better?
Direct effects of semaglutide on sleep architecture have not been established in clinical trials. Any improvement is most likely indirect — through weight loss and its effects on OSA severity and other weight-related conditions that disrupt sleep. Some patients also report sleep improving after the first few weeks of treatment, once early GI side effects settle.
Is sleep apnea a qualifying condition for GLP-1 treatment?
Under FDA labeling for Wegovy (semaglutide) and Zepbound (tirzepatide), adults with a BMI of 27 or higher plus at least one weight-related comorbidity — including obstructive sleep apnea — fall within the labeled indication. At Ondra Health, eligibility is determined by a licensed provider at Wasef Health, PC after reviewing your intake and health history. Compounded medications are not FDA-approved and are not covered by that labeling.
Should I stop using CPAP if I start semaglutide?
No. Do not discontinue CPAP based on starting a GLP-1 medication or on early weight loss. Any change requires repeat sleep testing and the agreement of the physician managing your sleep apnea. Stopping CPAP prematurely carries real cardiovascular and safety risk.
† This article is for informational purposes only and does not constitute medical advice. Compounded semaglutide and tirzepatide are not FDA-approved, are not reviewed by the FDA for safety, effectiveness, or manufacturing quality, and are not therapeutically equivalent to brand-name products. Clinical data cited: SURMOUNT-OSA (Malhotra A, Grunstein RR, Fietze I, et al. New England Journal of Medicine. 2024;391(13):1193-1205; doi:10.1056/NEJMoa2404881), which studied FDA-approved tirzepatide, not semaglutide and not compounded products. Trial statistics represent group averages — individual results vary. Nothing here should be used to guide changes to CPAP or other sleep apnea treatment; always consult the physician managing your sleep apnea. Wegovy® is a registered trademark of Novo Nordisk; Zepbound® is a registered trademark of Eli Lilly and Company. Ondra Health is not affiliated with either company.